Serum CA19.9 for Detecting High-Grade Dysplasia and Invasive Carcinoma in Patients With Intraductal Papillary Mucinous Neoplasm: A Systematic Review and Meta-Analysis - PubMed
4 hours ago
- #diagnostic accuracy
- #CA19-9
- #IPMN
- Current guidelines recommend serum CA19.9 assessment (cut-off ≥37 U/mL) as a worrisome feature for high-grade dysplasia (HGD) or invasive carcinoma (IC) in patients with intraductal papillary mucinous neoplasm (IPMN).
- Meta-analysis of 24 studies (5281 patients) showed CA19.9 had low sensitivity (0.35) but high specificity (0.90) for detecting HGD/IC, with an area under the curve of 0.78.
- CA19-9's diagnostic performance is insufficient as a standalone screening tool, with limited value for ruling out HGD/IC, though it may aid decision-making in moderate-risk cases.
- Future research should explore alternative cutoffs and dynamic trends to improve CA19-9's diagnostic accuracy in IPMN management.